stockportfolio.pro
Stocks / ANIP vs VCEL
ANIP vs VCEL
ANI Pharmaceuticals, Inc. and Vericel Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| ANI Pharmaceuticals, Inc. (ANIP) | Vericel Corporation (VCEL) | |
|---|---|---|
| Market cap | $1.8B | $1.9B |
| Revenue (latest FY) | $883.37M | $276.26M |
| Net income (latest FY) | $77.18M | $16.52M |
| Revenue growth (5y CAGR) | 33.5% | 17.3% |
| Net margin | 8.7% | 6.0% |
| Return on equity | 14.3% | 4.7% |
| P/E ratio | 20.8 | 86.6 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 3 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ANIP — free Open VCEL — freeFrequently asked questions
Which is bigger, ANIP or VCEL?
Vericel Corporation is larger by market capitalization — $1.9B versus $1.8B.
Which grows faster, ANIP or VCEL?
Over the last five fiscal years, ANI Pharmaceuticals, Inc. grew revenue faster — 33.5%/yr versus 17.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.